Insulet Co. (NASDAQ:PODD) Receives $277.13 Consensus Target Price from Brokerages

Insulet Co. (NASDAQ:PODD) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $277.13.

PODD has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Canaccord Genuity Group lifted their price objective on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. BTIG Research increased their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Citigroup boosted their price target on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Wells Fargo & Company increased their price objective on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th.

Insulet Stock Down 1.6 %

PODD stock opened at $283.08 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company’s 50-day moving average price is $270.27 and its 200 day moving average price is $241.58. Insulet has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a market cap of $19.86 billion, a P/E ratio of 48.47, a P/E/G ratio of 3.61 and a beta of 1.23.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. The company had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period in the previous year, the business earned $0.71 earnings per share. On average, research analysts expect that Insulet will post 3.22 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PODD. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Insulet by 10.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,000 shares of the medical instruments supplier’s stock worth $202,000 after acquiring an additional 95 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in Insulet during the 2nd quarter valued at approximately $830,000. Czech National Bank increased its holdings in Insulet by 7.0% during the 3rd quarter. Czech National Bank now owns 14,283 shares of the medical instruments supplier’s stock worth $3,324,000 after purchasing an additional 937 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Insulet by 26.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,683 shares of the medical instruments supplier’s stock valued at $392,000 after buying an additional 347 shares during the last quarter. Finally, Mather Group LLC. grew its position in shares of Insulet by 74.0% during the third quarter. Mather Group LLC. now owns 816 shares of the medical instruments supplier’s stock worth $190,000 after buying an additional 347 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.